Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy

Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody

(2016) Chao Wang et al.   ADVANCED MATERIALS

2016 update of the PRIDE database and its related tools

(2016) Juan Antonio Vizcaíno et al.   NUCLEIC ACIDS RESEARCH

Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy

(2015) Michael S. Goldberg   CELL

Synthetic Nanoparticles for Vaccines and Immunotherapy

(2015) Darrell J. Irvine et al.   CHEMICAL REVIEWS

Therapeutic cancer vaccines

(2015) Cornelis J.M. Melief et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor neoantigens: building a framework for personalized cancer immunotherapy

(2015) Matthew M. Gubin et al.   JOURNAL OF CLINICAL INVESTIGATION

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

(2015) Sebastian Kreiter et al.   NATURE

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy

(2015) Ronnie H. Fang et al.   Small

Nanoparticle-Based Immunotherapy for Cancer

(2014) Kun Shao et al.   ACS Nano

Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy

(2014) Jaeyun Kim et al.   NATURE BIOTECHNOLOGY

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

(2013) Silvia C. Formenti et al.   JNCI-Journal of the National Cancer Institute

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunotherapy

(2013) M. McNutt   SCIENCE

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Exploiting the Mutanome for Tumor Vaccination

(2012) J. C. Castle et al.   CANCER RESEARCH

Alarmins: awaiting a clinical response

(2012) James K. Chan et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nanoparticle PEGylation for imaging and therapy

(2011) Jesse V Jokerst et al.   Nanomedicine

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

Universal sample preparation method for proteome analysis

(2009) Jacek R Wiśniewski et al.   NATURE METHODS

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

(2009) James F Curtin et al.   PLOS MEDICINE

Self-Assembled Lipid−Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform

(2008) Liangfang Zhang et al.   ACS Nano